IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025 STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024 TYK2 oral degrader KT-294, with a TYK2 loss-of-function profile and expected biologics-like activity, planned to enter Phase 1 clinical trial in the first half of 2025 STAT3 degrader KT-333 and MDM2 degrader KT-253 expected to complete Phase 1a studies in 2024 and deliver additional proof-of-concept data defining path to late-stage development Well-capitalized, with cash in excess of $745 million1 and expected runway into the first half of 2027, enabling expansion into areas with large clinical and commercial opportunities Kymera to present company update and 2024 outlook at J.P.

IRAK4口服降解剂KT-474（SAR444656）预计将于2024年第四季度完成第二阶段HS和AD研究的登记，预计2025年上半年的topline数据STAT6口服降解剂KT-621具有类似dupilumab的活性，预计将于2024年下半年进入第一阶段临床试验TYK2口服降解剂KT-294，具有TYK2功能丧失特征和预期的生物制剂样活性，计划在2025年上半年进入1期临床试验STAT3降解剂KT-333和MDM2降解剂KT-253，预计在2024年完成1a期研究，并提供额外的概念验证数据，确定资本充足的后期开发路径，现金超过7.45亿美元1，预计将于2027年上半年进入跑道，使凯梅拉能够扩展到具有较大临床和商业机会的领域，并在J.P.上介绍公司最新情况和2024年前景。

Morgan Annual Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.

2024年1月9日（星期二）上午9:00 PT/下午12:00 ET WATERTOWN，Mass，2024年1月9日（Global NEWSWIRE）——临床阶段生物制药公司Kymera Therapeutics，Inc.（纳斯达克股票代码：KYMR）今天宣布了其2024年的公司目标，包括在免疫学和肿瘤学项目的最佳管道上取得的预期进展。

“Kymera has taken important steps toward our goal of building a fully integrated, global biotechnology company, demonstrating our ability to consistently deliver first- and best-in-class programs that target validated pathways with the potential to address large, underserved disease areas and create significant value for patients and shareholders,” said Nello Mainolfi, Ph.D., Founder, President and CEO, Kymera Therapeutics.

创始人内洛·梅诺尔菲（NelloMainolfi）博士说：“凯美拉（Kymera）已经朝着建立一家全面整合的全球生物技术公司的目标迈出了重要的一步，证明了我们有能力始终如一地提供一流和一流的计划，这些计划针对的是经过验证的途径，有可能解决大型服务不足的疾病领域，并为患者和股东创造重大价值。”，Kymera Therapeutics总裁兼首席执行官。

“We’r.

“We'r。